Hospital
SSM Regional Health Services
SSM Regional Health Services was paid $20.81M by Medicaid between Jan 2018 and Dec 2024, across 74 billing codes. Its largest line is X4011, State-specific procedure code — 24% of everything it billed.
33Billing provider infoSSM REGIONAL HEALTH SERVICES
JEFFERSON CITY, MO 65109
JEFFERSON CITY, MO 65109
33aNPI1518065523assigned 09/21/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$20.81M
24GClaims215,815
24DCodes billed74
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Missouri
Rank by total paid#17 of 74
Median peer was paid$4.44M
This provider vs. median4.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 23,757 | $5.45M | |
| 2019 | 24,062 | $5.16M | |
| 2020 | 21,893 | $2.15M | |
| 2021 | 33,852 | $895K | |
| 2022 | 43,401 | $2.22M | |
| 2023 | 39,615 | $2.68M | |
| 2024incomplete | 29,235 | $2.26M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| X4011 | State-specific procedure code | 24% | 16,664 | 15,418 | $5.06M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 15,608 | 14,972 | $2.32M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.5% | 8,682 | 8,217 | $1.76M |
| D7999 | 6.2% | 320 | 319 | $1.28M | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 5.8% | 20,738 | 18,985 | $1.22M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 5.2% | 13,383 | 12,580 | $1.09M |
| 80053 | Comprehensive metabolic panel | 4.5% | 18,716 | 17,257 | $931K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 3.6% | 4,622 | 3,088 | $752K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 3.2% | 12,759 | 12,554 | $657K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.0% | 5,758 | 5,417 | $618K |
| X4006 | 2.8% | 213 | 199 | $583K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.7% | 7,041 | 6,869 | $559K |
62 more codes
| 99285 | Emergency room visit (most serious) | 2.1% | 1,281 | $430K |
| X4003 | 1.7% | 5,519 | $352K | |
| 71046 | Radiologic examination, chest; 2 views | 1.6% | 1,514 | $340K |
| 81001 | 1.5% | 6,754 | $317K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.5% | 2,677 | $304K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.3% | 6,701 | $274K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.2% | 5,308 | $240K |
| 81025 | <1% | 3,752 | $202K | |
| 71045 | Radiologic examination, chest; single view | <1% | 4,699 | $186K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 9,920 | $148K |
| 81003 | <1% | 3,843 | $127K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,800 | $107K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,337 | $105K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,458 | $85K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 6,868 | $83K |
| 87428 | <1% | 3,045 | $68K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 553 | $63K |
| 87807 | <1% | 503 | $56K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,704 | $37K |
| 82962 | <1% | 884 | $36K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 162 | $35K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 1,431 | $34K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 655 | $32K |
| 80306 | <1% | 441 | $29K | |
| G0378 | Hospital observation service, per hour | <1% | 143 | $29K |
| 0240U | <1% | 340 | $28K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,117 | $20K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 242 | $19K |
| 84484 | <1% | 2,222 | $19K | |
| 83690 | <1% | 1,637 | $19K | |
| 83735 | <1% | 1,462 | $17K | |
| J3490 | Unclassified drugs | <1% | 2,106 | $15K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 110 | $15K |
| 80050 | General health panel | <1% | 145 | $15K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,194 | $13K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 916 | $9K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 81 | $9K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 380 | $9K |
| 80061 | Lipid panel | <1% | 430 | $8K |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 14 | $7K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 463 | $7K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 83 | $5K |
| 62323 | <1% | 14 | $4K | |
| 83880 | <1% | 207 | $4K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 53 | $3K |
| 72100 | <1% | 43 | $3K | |
| 87081 | <1% | 689 | $3K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 51 | $2K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 725 | $2K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 13 | $2K |
| 83605 | <1% | 225 | $2K | |
| Q3014 | Telehealth originating site facility fee | <1% | 134 | $2K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 103 | $1K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 13 | $1K |
| 85379 | <1% | 12 | $118.23 | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 16 | $82.76 |
| 85610 | <1% | 28 | $32.59 | |
| 85730 | <1% | 14 | $21.64 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 38 | $0.01 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 0% | 12 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 14 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAMM, EILEEN (REGIONAL VICE PRESIDENT, FINANCE)
Parent organizationSSM HEALTH CARE CORPORATION
| Provider | Location | Paid |
|---|---|---|
| SSM Medical Group, INC. | O Fallon, MO | $282K |
| SSM Health Care Group | Saint Louis, MO | $58K |
| SSM Health Care Group | Saint Louis, MO | $6K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.